Corsera Health
Corsera Health Raises $80M Series A | Once-Yearly Cardiovascular RNAi
Corsera Health Closes $80M Series A
Corsera Health, developing once-yearly RNAi treatments for cardiovascular diseases, has raised $80 million in Series A funding.
Key Highlights
- Novel once-yearly dosing approach
- Focus on cardiovascular diseases
- RNAi therapeutic platform
Company Overview
Corsera Health is developing RNA interference therapeutics that require only once-yearly dosing, potentially transforming treatment adherence for chronic cardiovascular conditions.
Company Info
Investors (2)
Share
Related Reports
Infisical Raises $40M Series B for AI Agent Security Infrastructure
Infisical raised a $40 million Series B at a $600 million valuation, led by Elad Gil, to expand security infrastructure for AI agents.
Vera Health Raises $28.5M Series A for Clinical AI Search
Vera Health raised a $28.5 million Series A led by Threshold Ventures to further develop its clinical evidence infrastructure and expand into additional healthcare markets.
Omnichat Raises US$10M Series A for Agentic Customer Experience Platform
Omnichat raised a US$10 million Series A led by Openspace Capital to scale its agentic AI platform, deepen R&D on Omni AI Agents and expand globally.
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free